News

Johnson & Johnson has announced a definitive agreement to acquire Halda Therapeutics OpCo, Inc., a clinical-stage biotechnology company developing next-generation targeted cancer…
Read More...

Biogen announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a unanimous positive opinion recommending approval of a high-dose…
Read More...

Johnson & Johnson has announced a definitive agreement to acquire Halda Therapeutics, a clinical-stage biotech developing oral, targeted cancer therapies using its proprietary…
Read More...

Merus N.V. and Halozyme Therapeutics have entered into a global, non-exclusive collaboration and license agreement to develop and potentially commercialize a subcutaneous formulation of…
Read More...

Solve Therapeutics, a clinical-stage biotechnology company developing best-in-class antibody-drug conjugates (ADCs) for solid tumors, has secured $120 million in an oversubscribed and…
Read More...

Sofinnova Partners, one of Europe’s leading life sciences venture capital firms, has closed its latest flagship fund, Sofinnova Capital XI, at €650 million ($750 million)—substantially…
Read More...

Sarepta Therapeutics has announced significant updates to the U.S. prescribing information for ELEVIDYS, the only approved gene therapy for Duchenne muscular dystrophy (DMD). The…
Read More...

The FDA’s approval of KOMZIFTI™ (ziftomenib) represents a significant milestone for patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) harboring NPM1 mutations—one…
Read More...

Eisai and Biogen announced that the UK Medicines and Healthcare products Regulatory Agency has approved a once-every-four-weeks IV maintenance dosing regimen for Leqembi (lecanemab), an…
Read More...

Mangoceuticals has launched MangoRx Direct and PeachesRx Direct, new programs offering customers direct access to FDA-approved GLP-1 medications Zepbound (tirzepatide) and Wegovy…
Read More...

MeiraGTx Holdings plc has announced a broad strategic collaboration with Eli Lilly and Company focused on advancing gene therapies for ophthalmic diseases, including a groundbreaking…
Read More...

Insilico Medicine, a clinical-stage company pioneering generative AI-driven drug discovery, has announced a new research collaboration with Eli Lilly and Company to jointly develop…
Read More...

SanegeneBio, a clinical-stage biotechnology company focused on RNAi therapeutics, has entered a global research and licensing collaboration with Eli Lilly and Company to develop…
Read More...

Harbour BioMed and Evinova have announced a strategic collaboration to integrate artificial intelligence (AI) and digital technologies into biologics research and development. The…
Read More...

Novartis has announced the opening of a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California — a major step in the company’s $23 billion,…
Read More...

Lyell Immunopharma, Inc., a late-stage clinical biotech company developing next-generation chimeric antigen receptor (CAR) T-cell therapies, has strengthened its solid tumor portfolio…
Read More...

Pelthos Therapeutics Inc. has acquired the U.S. commercialization rights to Xepi® (ozenoxacin) Cream, 1%, from Biofrontera Inc. and Ferrer Internacional S.A., expanding its dermatology…
Read More...

Alvotech and Advanz Pharma have announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisations for all four presentations of…
Read More...

Abzena, a leading end-to-end contract development and manufacturing organization (CDMO) for complex biologics and bioconjugates, has announced a strategic partnership with Mabqi, a…
Read More...

Novo Nordisk unveiled new findings from its OASIS 4 Phase 3 trial at ObesityWeek® 2025 in Atlanta, reinforcing the potential of oral semaglutide 25 mg as a treatment option for adults…
Read More...